News | May 12, 2014

AC Immune, Piramal Imaging Announce Out-licensing Agreement for the Development of Tau Protein Diagnostics for Alzheimer’s

Significant license agreement signals the importance of the development of Alzheimer’s Tau-PET-Imaging tracers

May 12, 2014 — AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd., have entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune’s Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer’s disease (AD) and potential Tau-related disorders.

The formation of Tau tangles in the human brain is recognized as one of two major hallmarks of Alzheimer’s disease pathology, with the other being beta-amyloid plaques. The development of the Tau tangle pathology appears to correlate well with cognitive decline, making it a potential strong target for diagnostic approaches. The availability of a Tau-PET tracer for imaging Tau tangles in the brain of patients would represent important progress towards relevant diagnostic endpoints and could be of significant value in guiding clinical trials for disease modifying AD therapeutics.

Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible for significant milestone payments on products achieving development goals in AD and other Tauopathies. Additionally, AC Immune is entitled to receive tiered royalties on net sales of products resulting from the partnership.

AC Immune will work in collaboration with Piramal Imaging to efficiently advance several lead candidates through late pre-clinical radio-pharmacology development. Piramal Imaging will have global rights for clinical development, manufacturing and commercialization of a Tau-PET Tracer resulting from the collaboration. Financial details were not disclosed.

The agreement between the two companies is based on a long-term relationship in which AC Immune has used Piramal Imaging’s beta-amyloid PET Tracer Neuraceq for imaging beta-amyloid plaques in the brain of patients undergoing Phase I/IIa clinical testing of AC Immune´s Alzheimer´s vaccine ACI-24.

Neuraceq received marketing authorization from the U.S. Food and Drug Administration (FDA) on March 19, 2014 for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. Safety and effectiveness of Neuraceq have not been established for monitoring responses to therapies. Neuraceq received similar approval by the EC four weeks earlier.

For more information: www.acimmune.com, www.piramal.com/imaging

Related Content

Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Neurofeedback Shows Promise in Treating Tinnitus

The standard approach to fMRI neurofeedback. Image courtesy of Matthew Sherwood, Ph.D.

News | Magnetic Resonance Imaging (MRI) | January 11, 2018
January 11, 2018 — Researchers using...
New Studies Show Brain Impact of Youth Football
News | Neuro Imaging | January 09, 2018
School-age football players with a history of concussion and high impact exposure undergo brain changes after one...
WEBINAR: Neuroimaging from a Clinical Perspective, sponsored by Philips Healthcare. How to better manage your MRI department.
Webinar | Magnetic Resonance Imaging (MRI) | January 08, 2018
The CME credit webinar "Neuroimaging from a Clinical Perspective," will explain how imaging departments can become mo
MRI Shows Brain Differences Among ADHD Patients
News | Neuro Imaging | January 02, 2018
Information from brain magnetic resonance images (MRIs) can help identify people with attention deficit hyperactivity...
Migraines Linked to High Sodium Levels in Cerebrospinal Fluid
News | Neuro Imaging | December 29, 2017
Migraine sufferers have significantly higher sodium concentrations in their cerebrospinal fluid than people without the...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
MRI Uncovers Brain Abnormalities in People With Depression and Anxiety

Significant cortical thickness differences among the three groups. All regions survived clusterwise-correction (p<0.001). Image courtesy of Youjin Zhao.

News | Neuro Imaging | December 22, 2017
Researchers using magnetic resonance imaging (MRI) have discovered a common pattern of structural abnormalities in the...
Videos | Neuro Imaging | December 21, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Overlay Init